Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Ajanta Pharma launches...

    Ajanta Pharma launches generic ADHD treatment drug in US

    Written by Ruby Khatun Khatun Published On 2017-11-23T10:15:22+05:30  |  Updated On 18 Aug 2021 9:33 AM GMT

    New Delhi: Drug firm Ajanta Pharma said it has launched generic Clonidine Hydrochloride extended-release tablets in the American market after receiving the US health regulator's nod.


    The company has launched the tablets in the strength of 0.1 mg in the US market through its wholly owned subsidiary Ajanta Pharma USA Inc, Ajanta Pharma said in a BSE filing.


    The product is a generic version of Concordia Pharmaceuticals Inc's Kapvay tablets, it added.


    The tablets are a part of the growing portfolio of products that the company has developed for the US market, Ajanta Pharma said.

    Clonidine Hydrochloride extended-release tablets are used for the treatment of attention deficit hyperactivity disorder (ADHD).

    The company currently has 22 final approvals for its abbreviated new drug applications (ANDAs) from the United States Food and Drug Administration (USFDA). It also has two tentative approvals and 15 ANDAs under review with the regulator, Ajanta Pharma said.

    Till date, the drug maker has launched 16 products in the US market.

    abbreviated new drug applications ADHD Ajanta Pharma American market attention deficit hyperactivity disorder BSE Clonidine Hydrochloride Concordia Pharmaceuticals drug extended-release tablets generic indian pharma news Kapvay tablets launches pharma news pharma news india US USFDA 
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Ruby Khatun Khatun
    Ruby Khatun Khatun
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier

      This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:

      Search only trustworthy HONcode health websites:

      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2020 Minerva Medical Treatment Pvt Ltd

      © 2020 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      X